← Back to all trials
Active Not Recruiting
NCT06633536
Real-life Treatment Outcomes of Ravulizumab in PNH
Conditions: Paroxysmal Nocturnal Haemoglobinuria
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 64
Sponsor: AstraZeneca
Location: Research Site Bialystok
Summary
The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.
Eligibility Criteria
Inclusion Criteria:
1. Adult (aged ≥18) patients with PNH receiving ravulizumab treatment in the frames of NDP in Poland.
2. Patients willing to participate in the study and signed ICF.
Exclusion Criteria:
1. Those who participated in ravulizumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first ravulizumab infusion through NDP.
2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Source: ClinicalTrials.gov (NCT06633536). StuddyBuddy aggregates publicly available trial information.
